ID   4T1/EPB
AC   CVCL_C0U6
DR   PRIDE; PXD027822
DR   Wikidata; Q112926990
RX   PubMed=34589084;
CC   Selected for resistance to: ChEBI; CHEBI:47898; 4'-epidoxorubicin (Epirubicin).
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Derived from site: In situ; Mammary gland; UBERON=UBERON_0001911.
CC   Breed/subspecies: BALB/cfC3H.
DI   NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0125 ! 4T1
SX   Female
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=34589084; DOI=10.3389/fimmu.2021.707298;
RA   Huang F., Pan N., Wei Y.-T., Zhao J.-J., Aldarouish M., Wang X.-R., Sun X.-T.,
RA   Wen Z.-F., Chen Y.-Q., Wang L.-X.;
RT   "Effects of combinatorial ubiquitinated protein-based nanovaccine and
RT   STING agonist in mice with drug-resistant and metastatic breast
RT   cancer.";
RL   Front. Immunol. 12:707298.1-707298.18(2021).
//